Bildkälla: Stockfoto

Alzecure Q4: Well-positioned pipeline - Redeye

Redeye reviews the case of Alzecure after the Q4 report, which offered no surprises, and continues to see an interesting neurology platform case with an exciting future. We adjust our base case somwhat due to external factors but reiterate our fundamental view.

Redeye reviews the case of Alzecure after the Q4 report, which offered no surprises, and continues to see an interesting neurology platform case with an exciting future. We adjust our base case somwhat due to external factors but reiterate our fundamental view.
Börsvärldens nyhetsbrev
ANNONSER